Contact Center Industry News

TMCNet:  Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax

[May 23, 2014]

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax

SAN DIEGO --(Business Wire)--

Batu Biologics, a biopharmaceutical company focused on the development and commercialization of cell therapies in the area of immune modulation, is pleased to announce the filing of U.S. patent application (61/987657) covering the composition and application of its flagship product, Vallovax. The novel cancer vaccine is specifically formulated to target the blood vessels that supply the tumor through induction of tumor autoimmunity and immune stimulation.

"Angiogenesis has proven to be a key factor in the proliferation of tumor cells within the host. Recent studies have revealed that without the formation of new blood vessels, tumors are unable to receive the blood supply they need to grow bigger than 1 to 2 mm in diameter," commented Andy J. Kim, Vice President of Scientific Research at Batu Biologics. "Testimony to the power of angiogenic blockade is the drug Avastin, which last quarter had sales of $1.6 billion1. Unfortunately, existing drugs that block angiogenesis only target specific pathways of this process, thus making them not universally applicable. An example of this is the withdrawal of FDA approval for treating metastatic breast cancer with Avastin in 20102. In contrast to previous approaches targeting cancer endothelium, Vallovax harnesses the power of the immune response, which allows for memory, specificity, and adaptability."

The Vallovax platform builds upon the work of Dr. Valentine Govallo, who recognized the placenta as one of the only natural systems that mimics cancer through immune suppression, angiogenesis, and metastasis. The "Govallo Vaccine", an uncharacterized placenta-based cancer immunotherapy, exhibited remarkable rates of remission: 66.7% 10-year survival rates for lung cancer patients3. Through recent developments in cancer research, Batu Biologics has identified and isolated the cells found in the "Govallo Vaccine" that combat angiogenesis and metastasis in cancer and plan to file an Investigational New Drug (IND) Application for non-small stage lung cancer to the FDA in 2014.

"Our Team is motivated to bring novel therapeutics to the forefront of medical research that use the power of the body's own immune system to extend life expectancy," commented Samuel C. Wagner, President and CEO. "Batu Biologics looks to pioneer the emerging field of cell therapy with novel therapeutics that improve the quality of life for late-stage patients with minimal toxic side-effects."

About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014.

Corporate Address:
9255 Towne Centre Drive
Suite 450
San Diego, CA (News - Alert) 92121

Laboratory Address:
Janssen Research and Development
3210 Merryfield Row
San Diego, CA 92121

3 Govallo, V. I. Immunology of Pregnancy and Cancer. Commack, NY: Nova Science, 1993. 195-210.

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...